Business Segments · Operating Income (Loss)
Biotechnology — Operating Income (Loss)
Danaher Biotechnology — Operating Income (Loss) increased by 53.4% to $540.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.3%, from $508.00M to $540.00M. Over 2 years (FY 2023 to FY 2025), Biotechnology — Operating Income (Loss) shows relatively stable performance with a -1.2% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ4 2025
Rolls up toOperating Income
How to read this metric
An increase indicates improved operational efficiency or stronger pricing power.
Detailed definition
The profit or loss generated by the biotechnology segment after deducting operating expenses from total revenue. This is...
Peer comparison
Standard segment-level profitability metric across all industries.
Metric ID:
dhr_segment_biotechnology_operating_income_lossHistorical Data
15 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $800.00M | $824.00M | $691.00M | $596.00M | $480.00M | $417.00M | $416.00M | $325.00M | $462.00M | $390.00M | $508.00M | $441.00M | $531.00M | $352.00M | $540.00M |
| QoQ Change | — | +3.0% | -16.1% | -13.7% | -19.5% | -13.1% | -0.2% | -21.9% | +42.2% | -15.6% | +30.3% | -13.2% | +20.4% | -33.7% | +53.4% |
| YoY Change | — | — | — | -25.5% | -41.7% | -39.7% | — | -45.5% | -3.8% | -6.5% | +22.1% | +35.7% | +14.9% | -9.7% | +6.3% |
Range$325.00M – $824.00M
CAGR-10.6%
Avg YoY Growth-8.5%
Median YoY Growth-6.5%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — operating income (loss)?
- Danaher (DHR) reported biotechnology — operating income (loss) of $540.00M in Q4 2025.
- How has Danaher's biotechnology — operating income (loss) changed year-over-year?
- Danaher's biotechnology — operating income (loss) increased by 6.3% year-over-year, from $508.00M to $540.00M.
- What is the long-term trend for Danaher's biotechnology — operating income (loss)?
- Over 2 years (2023 to 2025), Danaher's biotechnology — operating income (loss) has grown at a -1.2% compound annual growth rate (CAGR), from $1.91B to $1.86B.
- What does biotechnology — operating income (loss) mean?
- The core profit or loss generated by the biotechnology business segment.